Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.

Linardou H, Kalogeras KT, Kronenwett R, Alexopoulou Z, Wirtz RM, Zagouri F, Scopa CD, Gogas H, Petraki K, Christodoulou C, Pavlakis K, Koutras AK, Samantas E, Patsea H, Pectasides D, Bafaloukos D, Fountzilas G.

Anticancer Res. 2015 Jul;35(7):4023-36.

PMID:
26124351
2.

The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines.

Kritikou I, Giannopoulou E, Koutras AK, Labropoulou VT, Kalofonos HP.

Pharm Biol. 2013 Nov 5. [Epub ahead of print]

PMID:
24192333
3.

Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.

Koutras AK, Kotoula V, Papadimitriou C, Dionysopoulos D, Zagouri F, Kalofonos HP, Kourea HP, Skarlos DV, Samantas E, Papadopoulou K, Kosmidis P, Pectasides D, Fountzilas G.

Pharmacogenomics J. 2014 Jun;14(3):248-55. doi: 10.1038/tpj.2013.36. Epub 2013 Sep 24.

PMID:
24061601
4.

The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently.

Lymperatou D, Giannopoulou E, Koutras AK, Kalofonos HP.

Biomed Res Int. 2013;2013:147514. doi: 10.1155/2013/147514. Epub 2013 Jul 2.

5.

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.

Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, Gogas H, Christodoulou C, Koutras AK, Samantas E, Pectasides D, Bafaloukos D, Fountzilas G.

Breast Cancer Res. 2012 Nov 12;14(6):R145. doi: 10.1186/bcr3354.

6.

Angiogenesis as a therapeutic target in breast cancer.

Koutras AK, Starakis I, Lymperatou D, Kalofonos HP.

Mini Rev Med Chem. 2012 Oct;12(12):1230-8. Review.

PMID:
22512568
7.

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.

Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP.

Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16.

PMID:
21844885
8.

The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival.

Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP.

Cell Oncol (Dordr). 2011 Aug;34(4):381-91. doi: 10.1007/s13402-011-0038-4. Epub 2011 May 3.

PMID:
21538024
9.

Targeted therapy in colorectal cancer: current status and future challenges.

Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, Kalofonos HP.

Curr Med Chem. 2011;18(11):1599-612. Review.

PMID:
21428886
10.

Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.

Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2011 May;127(1):179-93. doi: 10.1007/s10549-011-1427-0. Epub 2011 Mar 9.

PMID:
21390496
11.

The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival.

Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP.

Anal Cell Pathol (Amst). 2010;33(5):177-89. doi: 10.3233/ACP-CLO-2010-0537. Erratum in: Cell Oncol (Dordr), 2011 Aug;34(4):407-8.

12.

Bevacizumab in the treatment of breast cancer.

Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP.

Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22. Review.

PMID:
19932567
13.

An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.

Giannopoulou E, Dimitropoulos K, Argyriou AA, Koutras AK, Dimitrakopoulos F, Kalofonos HP.

Invest New Drugs. 2010 Oct;28(5):554-60. doi: 10.1007/s10637-009-9290-0. Epub 2009 Jul 15.

PMID:
19603143
14.

The upgraded role of HER3 and HER4 receptors in breast cancer.

Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.

Crit Rev Oncol Hematol. 2010 May;74(2):73-8. doi: 10.1016/j.critrevonc.2009.04.011. Epub 2009 May 30. Review.

PMID:
19481955
15.

Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.

Koutras AK, Fountzilas G, Dafni U, Dimopoulos MA, Pectasides D, Klouvas G, Papakostas P, Kosmidis P, Samantas E, Gogas H, Briasoulis E, Vourli G, Petsas T, Xiros N, Kalofonos HP; Hellenic Cooperative Oncology Group.

Anticancer Res. 2008 Sep-Oct;28(5B):2913-20.

16.

Myelotoxicity in cancer patients treated with chemotherapy: negative or positive prognostic factor?

Koutras AK, Kalofonos HP.

Clin Cancer Res. 2008 Nov 15;14(22):7579. doi: 10.1158/1078-0432.CCR-08-1519. No abstract available.

17.

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G; Hellenic Cooperative Oncology Group (HeCOG).

Br J Cancer. 2008 Dec 2;99(11):1775-85. doi: 10.1038/sj.bjc.6604769. Epub 2008 Nov 4.

18.

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.

Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutras AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT, Kosmidis P.

Cancer Invest. 2008 Oct;26(8):784-93. doi: 10.1080/07357900801918611.

PMID:
18798073
19.

Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.

Koutras AK, Mastronikolis NS, Evans TR, Papadeas ES, Makatsoris T, Kalofonos HP.

Acta Oncol. 2008;47(6):1171-3. doi: 10.1080/02841860802213328. No abstract available.

PMID:
18615326
20.

Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.

Koutras AK, Gerolymos MK, Kontogeorgou E, Iconomou G, Vourli G, Tsiata E, Makatsoris T, Chrysanthopoulos C, Kalofonos HP.

J Chemother. 2007 Dec;19(6):724-30.

PMID:
18230557
21.

Brain metastasis in renal cell cancer responding to sunitinib.

Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP.

Anticancer Res. 2007 Nov-Dec;27(6C):4255-7.

22.

The epidermal growth factor receptor family in breast cancer.

Koutras AK, Evans TR.

Onco Targets Ther. 2008 Sep 1;1:5-19.

23.

Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature.

Koutras AK, Talampuka G, Pagoni N, Thomopoulos KC, Kalliolias G, Kalogeropoulou C, Kalofonos HP.

J BUON. 2007 Apr-Jun;12(2):281-3. Review.

24.

Capecitabine-induced hypertriglyceridemia: a report of two cases.

Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP.

Anticancer Res. 2006 May-Jun;26(3B):2249-51.

25.

Pilot study of nitric oxide-donating aspirin in patients with pancreatic cancer pain.

Iconomou G, Kalofonos HP, Koutras AK, Vagenakis AG, Rigas B.

J Support Oncol. 2006 Apr;4(4):168. No abstract available.

PMID:
16669458
26.

Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.

Kourea HP, Koutras AK, Zolota V, Grimani I, Tzoracoeleftherakis E, Koukouras D, Fountzilas G, Gogas H, Kyriakou K, Adamou A, Kalofonos HP.

Anticancer Res. 2006 Mar-Apr;26(2B):1657-68.

27.

Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis.

Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, Mouzaki A, Kalofonos HP.

Oncology. 2004;67(2):179-82. Review.

PMID:
15539924
28.

Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

Kourea HP, Koutras AK, Scopa CD, Marangos MN, Tzoracoeleftherakis E, Koukouras D, Kalofonos HP.

Mol Pathol. 2003 Dec;56(6):328-35.

29.

Surgical management of cerebral metastases from non-small cell lung cancer.

Koutras AK, Marangos M, Kourelis T, Partheni M, Dougenis D, Iconomou G, Vagenakis AG, Kalofonos HP.

Tumori. 2003 May-Jun;89(3):292-7.

PMID:
12908786
30.

Fecal secretory immunoglobulin A in breast milk versus formula feeding in early infancy.

Koutras AK, Vigorita VJ.

J Pediatr Gastroenterol Nutr. 1989 Jul;9(1):58-61.

PMID:
2778570
31.

Effect of iron-fortified formula on SIgA of gastrointestinal tract in early infancy.

Koutras AK, Vigorita VJ, Quiroz E.

J Pediatr Gastroenterol Nutr. 1986 Nov-Dec;5(6):926-30.

PMID:
3794912
32.

Myositis with mucocutaneous lymph-node syndrome.

Koutras AK.

N Y State J Med. 1980 Jun;80(7 Pt 1):1138-9. No abstract available.

PMID:
6930583

Supplemental Content

Loading ...
Support Center